Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
Understanding the real-world adverse event risks of novel biosimilar drugs
FY 2022-23
Summary
Biologics are newer drugs that are made by living organisms or cells. They have greatly improved outcomes for many medical conditions that were previously not well treated, such as auto-immune diseases, but have been associated with high costs. Now that the patents for many innovator biologics have expired, biosimilars have entered the market. For a biosimilar to be approved, clinical trials must demonstrate that it has similar efficacy and safety as the innovator biologic. Biosimilars often cost much less than innovator biologics. They can improve accessibility for patients and sustainability for payers such as the Ontario government. However, uptake of biosimilars has been low. Clinicians and patients are reluctant to use biosimilars because of less evidence, especially when patients have responded positively to innovator biologics. Although biosimilars are supported by clinical trials, real-world evidence is limited and largely focused on efficacy rather than safety. The proposed research will: (1) describe the safety risks and characteristics of patients on novel biosimilars, and (2) compare the safety risks between patients who switch from the innovator to a biosimilar, versus those who continuously use the innovator. The findings can help support important clinical and policy decisions that can affect the disease management of thousands of Ontarians.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
486321
Name
Ho Martin K
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Understanding the real-world adverse event risks of novel biosimilar drugs
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Auto-Immune Diseases; Biologic Drugs; Biosimilars; Comparative Drug Safety; Health Policy; Pharmacoepidemiology
Abstract
Biologics are newer drugs that are made by living organisms or cells. They have greatly improved outcomes for many medical conditions that were previously not well treated, such as auto-immune diseases, but have been associated with high costs. Now that the patents for many innovator biologics have expired, biosimilars have entered the market. For a biosimilar to be approved, clinical trials must demonstrate that it has similar efficacy and safety as the innovator biologic. Biosimilars often cost much less than innovator biologics. They can improve accessibility for patients and sustainability for payers such as the Ontario government. However, uptake of biosimilars has been low. Clinicians and patients are reluctant to use biosimilars because of less evidence, especially when patients have responded positively to innovator biologics. Although biosimilars are supported by clinical trials, real-world evidence is limited and largely focused on efficacy rather than safety. The proposed research will: (1) describe the safety risks and characteristics of patients on novel biosimilars, and (2) compare the safety risks between patients who switch from the innovator to a biosimilar, versus those who continuously use the innovator. The findings can help support important clinical and policy decisions that can affect the disease management of thousands of Ontarians.
Competitiondate
202212
Approvedterm2
1 yr 0 mth
Pinamesdelim
Ho, Martin K
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~